NKTX vs. FATE, PHAT, CYAD, NK, ARQT, MNKD, ABCL, DAWN, MIRM, and CALT
Should you be buying Nkarta stock or one of its competitors? The main competitors of Nkarta include Fate Therapeutics (FATE), Phathom Pharmaceuticals (PHAT), Celyad Oncology (CYAD), NantKwest (NK), Arcutis Biotherapeutics (ARQT), MannKind (MNKD), AbCellera Biologics (ABCL), Day One Biopharmaceuticals (DAWN), Mirum Pharmaceuticals (MIRM), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "medical" sector.
Nkarta (NASDAQ:NKTX) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations, community ranking and risk.
In the previous week, Fate Therapeutics had 2 more articles in the media than Nkarta. MarketBeat recorded 5 mentions for Fate Therapeutics and 3 mentions for Nkarta. Nkarta's average media sentiment score of 0.78 beat Fate Therapeutics' score of 0.77 indicating that Nkarta is being referred to more favorably in the media.
Fate Therapeutics received 431 more outperform votes than Nkarta when rated by MarketBeat users. However, 72.73% of users gave Nkarta an outperform vote while only 68.62% of users gave Fate Therapeutics an outperform vote.
Nkarta has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,933.79%. Nkarta's return on equity of -34.13% beat Fate Therapeutics' return on equity.
80.5% of Nkarta shares are owned by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are owned by institutional investors. 8.7% of Nkarta shares are owned by insiders. Comparatively, 5.0% of Fate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Nkarta has higher earnings, but lower revenue than Fate Therapeutics. Nkarta is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.
Nkarta has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500.
Nkarta presently has a consensus price target of $17.83, indicating a potential upside of 175.63%. Fate Therapeutics has a consensus price target of $6.58, indicating a potential upside of 85.97%. Given Nkarta's stronger consensus rating and higher probable upside, analysts clearly believe Nkarta is more favorable than Fate Therapeutics.
Summary
Nkarta beats Fate Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Nkarta News Delivered to You Automatically
Sign up to receive the latest news and ratings for NKTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
